The distinctive carbohydrate side chains of IgA1 molecules play a pivotal role in the pathogenesis of IgA nephropathy (IgAN) (8-10). IgA1 contains a hinge region (HR) between the first and second heavy-chain constantregion domains with a high content of proline (P), serine (S) and threonine (T) (Figure 1 ). Several groups have identified three to five Olinked glycan chains within the IgA1 HR (11) (12) (13) (14) (15) . In normal human serum IgA1, glycosylated sites have been localized to S/T residues 225, 228, 230, 232, and 236 by N-terminal sequencing methods (14) showing that S/T residues 228, 230, and 232 were occupied in most IgA1 molecules (14). IgA1 O -linked glycans consist of N -acetylgalactosamine (GalNAc) with a ß1,3 linked galactose (Gal) (11, 14, 16) . Sialic acid (NeuAc) may be attached to GalNAc by an α2,6 linkage or to Gal by an α 2,3 linkage (11, 14, 16) .
The distinctive carbohydrate side chains of IgA1 molecules play a pivotal role in the pathogenesis of IgA nephropathy (IgAN) (8) (9) (10) . IgA1 contains a hinge region (HR) between the first and second heavy-chain constantregion domains with a high content of proline (P), serine (S) and threonine (T) (Figure 1 ). Several groups have identified three to five Olinked glycan chains within the IgA1 HR (11) (12) (13) (14) (15) . In normal human serum IgA1, glycosylated sites have been localized to S/T residues 225, 228, 230, 232, and 236 by N-terminal sequencing methods (14) showing that S/T residues 228, 230, and 232 were occupied in most IgA1 molecules (14) . IgA1 O -linked glycans consist of N -acetylgalactosamine (GalNAc) with a ß1,3 linked galactose (Gal) (11, 14, 16) . Sialic acid (NeuAc) may be attached to GalNAc by an α2,6 linkage or to Gal by an α 2,3 linkage (11, 14, 16) .
Carbohydrate composition of O-linked glycans in the HR of normal human serum IgA1 is variable and the prevailing forms include Gal-GalNAc disaccharide and its mono-and di-sialylated forms (11, 12, 14) . A variant with terminal GalNAc or sialylated GalNAc is rare for normal serum IgA1 (12, 14) , but is more common in IgAN patients (8, 10, (17) (18) (19) (20) .
Recent reports from several laboratories support the earlier findings that O-linked glycans in the hinge region of some IgA1 molecules in the circulation of IgAN patients are deficiently galactosylated (8, (17) (18) (19) (20) (21) (22) . The Gal-deficient IgA1 in the circulation is exclusively present in circulating immune complexes and is mostly a J-chain-containing polymer (20) . In the absence of Gal, the terminal sugar is GalNAc (19, 20) . Subsequently, these aberrant O-glycans or HR glycopeptides (23, 24) are recognized by naturally occurring antibodies with anti-glycan or anti-HR peptide specificities (20, 24) and thus circulating immune complexes are formed (25) . It is hypothesised that these Gal-deficient IgA1-containing circulating immune complexes are not efficiently cleared in IgAN patients and thus deposit in the mesangium where they bind t o and activate the resident mesangial cells, inducing cellular proliferation and matrix overproduction (9, 26) . In fact, these Galdeficient IgA1-containing complexes bind t o mesangial cells more efficiently than uncomplexed IgA1 or similarly-sized IgA1-containing complexes from healthy controls (25) . Furthermore, Gal-deficient IgA1 was detected in glomerular immune deposits (27, 28) . These observations support the hypothesis that aberrantly glycosylated IgA1-containing immune complexes participate in the pathogenesis of IgAN (4, 9, 22, 26) .
Available techniques for analysis of IgA1 O-glycosylation, such as lectin binding assays, can identify the presence of Galdeficient O-glycan chains (27) (28) (29) (30) (31) . However, it is not known whether the Gal deficiency in IgAN patients occurs randomly or preferentially at specific sites. Mass spectrometric analysis of IgA1 HR O-glycosylation has characterized the heterogeneity of glycoforms (15, 28, 30) but has not localized specific sites of O-glycosylation. Tandem mass spectrometry (MS/MS) has become a standard tool for the structural analysis of carbohydrates (for a review of complex carbohydrate mass spectrometry see (32) ). Characterization of a carbohydrate or glycopeptide species is done tandem-in-time by isolation of a given precursor ion followed by fragmentation and detection of the resulting fragment (product) ions. Collision Induced Dissociation (CID) of carbohydrates can define the complete sequence and linkages of the sugars in complex carbohydrate structures (32) . Although localization of sites of glycan attachment in O-linked glycopeptides (32) (33) (34) (35) and N-linked glycopeptides (36-38) is possible by CID fragmentation, the task is complicated by the dominance of fragments resulting from cleavage of glycosidic linkages rather than peptide backbone cleavages in the tandem (CID) MS/MS spectra. Also, as the size and number of glycan chains increase, so does the dominance of glycosidic fragments (34) .
Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS) offers two complementary fragmentation techniques for analysis of protein glycosylation by tandem mass spectrometry (MS/MS) (39) . Infrared multiphoton dissociation (IRMPD) (40) induces selective dissociation of the glycosidic bonds on N -linked glycans of glycopeptides. Electron capture dissociation (ECD) fragmentation, first demonstrated by Zubarev et al. (41) and recently reviewed (42, 43) , results in complementary cleavage of the backbone N-Cα bond with minimal loss of post-translational modifications (44, 45 (20) , suggesting that this IgA1 protein has properties similar to the aberrantly glycosylated IgA1 present in the circulation of IgA nephropathy patients.
We observed a heterogenous population of glycosylated IgA1 HR as in prior studies (15, 28, 30) . FT-ICR MS/MS experiments localized sites of O-glycosylation in the IgA1 HR. Four and five glycan chains composed of either a GalNAc-Gal disaccharide or a GalNAc monosacharide were localized to five of the ten possible sites of O -glycosylation in the myeloma IgA1HR. These analytical approaches will be used in the future for characterization of O-glycans in IgA1 from IgAN patients.
Materials and Methods
Synthesis of IgA1 HR peptide and glycopeptide variants -A panel of 19-mer hinge region peptide and glycopeptides, with an alpha-Olinked GalNAc residue, corresponding to the amino acid sequence of the human IgA1 HR were synthesized by and purchased from the Peptide Institute Inc. (Osaka, Japan). Purity and molecular weight of the preparations were confirmed by HPLC and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). HR peptide and glycopeptides used: HP: V-P-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S; 4-HP: V-P-S-(GalNAc)T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S; 7-HP: V-P-S-T-P-P-(GalNAc)T-P-S-P-S-T-P-P-T-P-S-P-S; 9-HP: V-P-S-T-P-P-T-P-(GalNAc)S-P-S-T-P-P-T-P-S-P-S; 11-HP: V-P-S-T-P-P-T-P-S-P-(GalNAc)S-T-P-P-T-P-S-P-S; 15-HP: V-P-S-T-P-P-T-P-S-P-S-T-P-P-(GalNAc)T-P-S-P-S; 4-15-HP: V-P-S-(GalNAc)T-P-P-(GalNAc)T-P-(GalNAc)S-P-(GalNAc)S-T-P-P-(GalNAc)T-P-S-P-S.
Isolation of IgA1 HR glycopeptide from a myeloma IgA1 (Mce) -HR from pIgA1 myeloma protein (Mce) was isolated as a trypicpeptic fragment following the procedure described by Wolfenstein-Todel and colleagues (48, 49) .
The resultant preparation was lyophilized and dissolved in water before analyses.
Monosaccharide compositional analysis -The monosaccharides from purified myeloma IgA1 HR were determined as trifluoroacetates of methyl-glycosides by gas chromatography as described previously (50) . The analyses were performed with a gas chromatograph (Model 5890, Hewlett-Packard, Sacramento, California, USA equipped with a 25 m fused silica (0.22 mm inner diameter) OV-1701 WCOT column (Chrompack, Bridgewater, New Jersey, USA) electron capture detector and a HP model 3396 integrator. About 10 µg of HR glycopeptide was used for the analysis.
Sample preparation -For electrospray ionization (ESI) experiments, synthetic IgA1 HR samples (5 mM in 1:1 water:methanol, 2% acetic acid) were micro-electrosprayed (51) from an emitter consisting of a 50 µm i.d. fused silica capillary that had been mechanically ground to a uniform thin-walled tip (52) at a flow rate of 300 nL/min. For separated myeloma IgA1 HR glycopeptides, samples were desalted with a C 1 8 ZipTip (Millipore, City, MA) into 30 µ L of a 4:1 acetonitrile:water solution containing 0.1% formic acid. Desalted samples were then microelectrosprayed as above at a flow rate of 200-400 nL/min or from a chip-based electrospray interface (NanoMate, Advion, Ithaca, NY).
FT-ICR MS of IgA1 HR glycopeptides -IgA1
HR glycopeptides were analyzed with a homebuilt 9.4 Tesla ESI Q FT-ICR mass spectrometer (47, 53) under the control of a modular ICR data acquisition system (MIDAS) (54, 55) . Ions were transported through a Chaitstyle atmosphere-to-vacuum interface (56) and accumulated in a linear octopole ion trap (57), modified to allow improved ion ejection along the z-axis (58 For ECD of synthetic IgA1 HR glycopeptides, quadrupole and SWIFT-isolated ion precursor populations were irradiated with electrons for 10-100 ms. During the ECD fragmentation event, the trap electrodes were set at 10 V, the cathode was biased at -10 V, and the extraction grid was pulsed to +200 V. Immediately following the ECD event, the trap electrodes were reset to 2 V, and potentials of 5 V for the grid and 10 V for the cathode were applied for 1 ms to remove the remaining electrons. At all other times the cathode bias voltage was -0.1 V and the grid potential was -200 V. The cathode heating power was 11 W, corresponding to an electron emission current of ~300 nA.
FT-ICR MS/MS of IgA1 HR glycopeptides
Ions were frequency-sweep ("chirp") excited (48 to 640 kHz, at 150 Hz/µs) and detected in direct mode (512 kword timedomain data). Displayed spectra represent the sum of 100-200 time-domain transients. The ECD FT-ICR MS/MS spectra were internally frequency-to-m/z calibrated with respect to the precursor and the charge reduced species.
For IRMPD of isolated myeloma IgA1 HR glycopeptides, quadrupole and SWIFTisolated ion precursor populations were photon irradiated for 100 ms at 20% laser power (8 W). Ions were frequency-sweep excited (48 to 480 kHz, at 150 Hz/µs) and detected in direct mode (512 kword time-domain data). Displayed spectra represent the sum of 50 time domain transients.
For AI-ECD of isolated myeloma IgA1 HR glycopeptides, quadrupole and SWIFT isolated ion precursor populations were photon irradiated for 300 ms at 16% (6.4W) or 20% (8 W) laser power. Immediately following photon irradiation, the isolated ion precursor populations were irradiated with electrons for 10 or 20 ms. During the electron irradiation event, the trap electrodes were set to 4-10 V, the cathode was biased at -4 or -5 V, and the extraction grid was pulsed to +5 V. Immediately following the ECD event, the trap electrodes were reset to 2 V, and potentials of 5 V for the grid and +10 V for the cathode were applied for 100 ms to remove the remaining electrons (66, 67) . At all other times the cathode bias voltage was -0.1 V and the grid potential was -200 V. The cathode heating power was 11 W, corresponding to an electron emission current of ~300 nA. Ions were frequency-sweep excited (48 to 480 kHz or 45 to 480 kHz, at 150 Hz/µs) and detected in direct mode (1 Mword time-domain data). Displayed spectra represent the sum of 60-100 time domain transients. The AI-ECD FT-ICR MS/MS spectra were internally frequency-to-m/z calibrated with respect to the precursor, the charge reduced species, and z 5 ions. All FT-ICR MS and MS/MS spectra were analyzed by use of the MIDAS analysis software package (55) .
RESULTS

FT-ICR MS/MS of synthetic HR peptide and glycopeptides
ECD fragmentation typically cleaves the peptide backbone N-Cα bond with minimal loss of post-translational modifications. The exception to that rule is proline, which is cyclic around the N-Cα bond and does not cleave into the characteristic N-terminal c and C-terminal z fragments (68) seen by ECD (69) . The IgA1 HR is a proline-rich segment with 9-10 S/T residues interspersed among 12 prolines. For that reason, pilot experiments to determine the feasibility of characterizing IgA1 HR glycosylation sites by ECD FT-ICR MS/MS were performed with synthetic HR peptides. Figure 2 shows the FT-ICR mass spectra obtained following ECD of the peptides HP, 9-HP, 4-HP, and 4-15-HP. Table 1 In contrast to MS/MS of the unglycosylated peptide, no z 1 6 fragment was detected. The results allow location of the glycan to S3 or T4.
Singly-glycosylated peptides 7-HP and 11-HP were also subjected t o ECD analysis (data not shown). In both cases the ECD fragmentation pattern allowed for unambiguous localization of the glycan (T7 in 7-HP; and S11 in 11-HP). ECD analysis of the quintuply-glycosylated peptide 4-15-HP (Figure 2 D) enabled unambiguous localization of four of the glycans to T7, S9, S11, and T15, and the final glycan to S3 or T4.
These results demonstrate that direct assignment of native IgA1 HR O-glycosylation sites is possible by ECD FT-ICR MS.
Analysis of heterogeneity in synthetic HR glycopeptides
To assess the ability of ECD fragmentation to distinguish between homogeneous and heterogeneous glycosylation, mixtures of the synthetic peptides were subjected to ECD and their fragmentation patterns examined. Figure 3 shows the ECD FT-ICR mass spectrum obtained from a 1:1 mixture of peptides, 7-HP and 9-HP. The fragments confirm the heterogeneity in the glycosylation pattern and localize sites of glycosylation to T7 and S9. The c 6 + , but no c 1 0 , fragments were detected, demonstrating glycosylation at S9. There was no evidence for glycosylation at positions 11 and 15.
A 1:1:1 mixture of 7-GP, 11-GP and 15-HP was analyzed by ECD FT-ICR MS (not shown). The results confirmed heterogeneity in the glycosylation pattern. Glycosylation at positions 11 and 15 was confirmed, as was the absence of glycosylation at position 4. However, evidence for glycosylation at positions 9 and 11 was ambiguous. Similarly, ECD analysis of a mixture of all five peptides confirmed heterogeneity, and the presence of glycosylation at positions 4 and 15. The presence of glycosylation at positions 7, 9, and 11 was ambiguous. The ambiguity associated with heterogeneity can be attributed to the absence of z fragments bracketing the residues of interest in these mixtures. The results for 7-HP:9-HP were unambiguous because the glycans are at adjacent glycan attachment sites. Thus the lack of z fragments did not interfere with the interpretation of the results. Similarly, unambiguous results would also be expected for mixtures: 4-HP and 7-HP; 9-HP and 11-HP; and 11-HP and 15-HP.
FT-ICR MS/MS analysis of isolated myeloma IgA1 HR glycopeptides
HR glycopeptides were isolated from myeloma IgA1 by trypsin-pepsin digestion of IgA1 as previously described (49) . Monosaccharide compositional analysis by gasliquid chromatography determined the presence of GalNAc, Gal, and NeuAc (results not shown), indicating that HR was free of contaminating glycopeptides containing N -linked glycans. Although no species corresponding to an unglycosylated IgA1 HR were detected, the series of ions suggests that the isolated IgA1 HR peptide is a heterogenous mixture of differentially glycosylated species, as seen in other myeloma IgA1 HR by mass spectrometry and lectin-binding assays (15, 28, 30) . The single species, m/z 1600.033 3+ , was isolated (Figure 4 (middle)), and fragmented by infrared multiphoton dissociation (IRMPD, Figure 4 (bottom)). The IRMPD product ion spectrum shows a series of triply and doubly charged ions corresponding to the loss of multiple Gal (162.05) and GalNAc (203.08) residues from the isolated parent ion.
To (Figure 4) , and the confirmed amino acid sequence of the de-glycosylated IgA1 HR peptide ( Figure 5 ), glycan structures for the mixture may be inferred for the dominant series of ions seen in Figure 4 , and are listed in Table  2 . ESI FT-ICR MS analysis of sialylated IgA1 HR indicated a similar heterogeneous mixture of differentially glycosylated species including multiple NeuAc residues (data not shown). For localization of sites deficient in Gal by ECD FT-ICR MS/MS, myeloma IgA1 HR trypsin-pepsin preparations were desialylated to reduce the IgA1 HR glycopeptide heterogeneity for each sample.
Localizing sites of O-glycosylation by ECD FT-ICR MS/MS
Based on pilot studies with synthetic IgA1 HR and the identification of multiply glycosylated variants in the isolated myeloma IgA1 HR, ECD for three myeloma IgA1 HR glycopeptides serves to localize specific sites of O -glycan attachment.
Unlike ). Typically, y ions represent a minor fragmentation channel in ECD (69) .
Much more extensive c and z • ECD fragmentation may be achieved by prior or simultaneous activation by infrared radiation (at lower IR power than would be used for direct IRMPD) (45, 47, 70) . Figure 6 (11, 14) . Localization of Oglycosylation sites proceeds in a stepwise fashion by identification of fragments that come from the N-terminus (b and c) followed by fragments that come from the C-terminus (y and z) to identify (and eliminate) specific serines and threonines with (or without) attached glycans. From the N-terminus, detection of b 7 , c 8 , which indicate that the remaining 2 glycan chains are attached Nterminal to S 230 (4 possible sites), but since T 217 and S 224 are eliminated by the presence of c 8 and c 9 , and because the first glycan chain is similarly assigned to T 225 , the only remaining site of glycan attachment is T 228 .
With the successful localization of 4 glycan chains in a single ion species, we chose two other IgA1 HR glycoforms seen in the original series (see Figure 4 and 3+ ions after AI-ECD fragmentation). The fragmentation pattern (17 fragment ions) is similar to that of the previous hinge region glycoform. Three GalNAc-Gal disaccharide chains are localized to T 225 , T 228 , and S 230 as before. The difference between z 1 5 and z 1 4 corresponds to the mass of a serine residue + GalNAc, indicating a glycan chain composed of a GalNAc monosaccharide at S 232 , thus localizing a site of Gal-deficiency. Figure 8 shows 
FT-ICR MS characterization of IgA1 HR
IgA1 HR-containing trypsin-pepsin fragment is a proline rich sequence with a cluster of ten serines and threonines that are potential sites of O -glycan attachment (V 216 -L 246 ) (71, 72) . Because c and z fragments rarely arise within proline (69), initial ECD FT-ICR MS/MS experiments were performed with a synthetic version of IgA1 HR. ECD FT-ICR MS/MS of synthetic IgA1 HR showed that ECD fragmentation results in enough products t o localize each possible site of O -g l y c a n attachment (Figure 2) . ECD of several versions of synthetic IgA1 HR with a single GalNAc monosaccharide attached at various sites can distinguish between homogeneous and heterogeneous populations of glycosylated IgA1 HR (e.g., Figure 3 ).
For HR isolated from myeloma IgA1, IRMPD successfully confirms the sequence of the de-glycosylated hinge region. However, IRMPD of the glycosylated myeloma IgA1 HR demonstrates the complexity of identifying multiple sites of O-glycan attachment within a single glycoform. Although the loss of multiple GalNAc and Gal residues is easily recognized (Figure 4, bottom) , identifying sites of O-glycan chain attachment and which chain is Galdeficient by IRMPD or other slow-heating methods (i.e. CID) is impossible for several reasons: 1) the IgA1 HR glycan chains are all similar or identical in composition, 2) the 10 serines and threonines are clustered, and 3) the HR amino acid sequence is a tandem repeat (49) . All of these factors prevent the selective removal of a single glycan chain by slow-heating methods and subsequent determination of its site of attachment by neutral loss. Only with the glycan chains intact could the site deficient in Gal be identified.
Based on our pilot experiments, ECD fragmentation of the HR thus offered the greatest promise for localization of sites of O-glycan attachment.
Identification of IgA1 HR O-glycosylation sites
The pathogenesis of IgAN is characterized by immunodeposits in the renal messangium. These immunodeposits contain IgA1 with incompletely galactosylated O-linked glycans in the HR (27, 28) . It is not known whether the Gal deficiency in IgAN occurs randomly or at specific sites. In analysis of IgA1 HR O-glycosylation, previous studies have used a combination of techniques to assess sites of Oglycan attachment (N-terminal sequencing and IgA specific proteases (14) ), sites deficient in Gal (glycan specific lectins + specific and nonspecific proteases (27-31)), and O-glycan heterogeneity (MALDI-TOF MS (28, 30) ). The present results show that FT-ICR MS and tandem MS can achieve the equivalent of all of these analyses from a single preparation of IgA1 HR.
The HR glycopeptide, V 216 -L 246 , was isolated from myeloma IgA1 by a trypsinpepsin digest. The initial FT-ICR MS spectrum showed a series of species corresponding to the predicted mass of V 216 -L 246 with the addition of varying numbers of GalNAc and Gal residues (Figure 4, top) . This series is consistent with previous mass analyses of the heterogeneity of O-glycosylation in the hinge region (15, 28, 30) . (Figure 7) , four O-glycan chains could again be localized to the same sites, with a monosaccharide (GalNAc) instead of a disaccharide attached at S 232 . The AI-ECD product ion spectrum of a third glycoform (Figure 8 ) localizes the same sites of attachment for four GalNAc-Gal disaccharide chains plus a fifth GalNAc monosaccharide at either T 233 or T 236 .
Baenziger and Kornfeld (11) reported that IgA1 myeloma protein (Oso, different from the IgA1 myeloma reported here) contained O-glycans at S residues 224, 230, 232, 238, and 240, with a GalNAc monosaccharide at S 224 . Mattu et al. (14) localized sites of attachment to HR residues T 225 , T 228 , S 230 , S 232 , and T 236 from pooled human serum IgA1, with a fraction of the population not glycosylated at residues T 225 and T 236 . In our analysis, T 225 in the three HR glycoforms always contained an attached GalNAc-Gal disaccharide. These differences could be attributed to the difference in source of the IgA1 HR. One distinct difference is that N-terminal sequencing methods sequence the entire population of IgA1 HR isolated from IgA1, whereas we isolate individual HR glycoforms and sequence by AI-ECD fragmentation. It is also worth noting that previously established methods rely on the depression or absence of expected signal at particular cycles in the amino acid sequencing (14) , whereas an AI-ECD product ion spectrum directly identifies sites with and without an attached glycan. Recently, it was discovered that a single enzyme, GalNAc-transferase 2, is responsible for addition of GalNAc to IgA1 HR sites (73) . Although there is a clear site preference, the enzyme is capable of adding GalNAc to all potential sites in IgA1 HR. Thus, the determination of which of the potential sites in IgA1 HR are glycosylated is likely related to the properties and regulation of this single enzyme. Differential regulation of this enzyme in different IgA1-producing cells may therefore result in the heterogeneity of sites with attached glycans. We believe that the FT-ICR MS/MS techniques described here will be applicable to the analysis of O-linked glycans of IgA1 isolated from patients with diseases such as IgAN.
Conclusion
The present approach represents a new level of analysis of aberrant O-glycosylation found in IgA-associated diseases. Previous mass spectrometric studies of IgA1 heterogeneity concluded that the three glycoforms characterized here are found in normal human serum (15 Table 1 : Fragment positive ions following ECD of the peptides, HP (V-P-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S); 9-HP (V-P-S-T-P-P-T-P-(GalNAc)S-P-S-T-P-P-T-P-S-P-S); 4-HP (V-P-S-(GalNAc)T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S); and 4-15-HP (V-P-S-(GalNAc)T-P-P-(GalNAc)T-P-(GalNAc)S-P-(GalNAc)S-T-P-P-(GalNAc)T-P-S-P-S). The reported m/z values are for the monoisotopic mass. (Figure 4 A) . Based on the determined amino acid sequence of the isolated IgA1 HR ( Figure 5 ) and the known glycan compositions, the number of attached GalNAc and Gal residues are predicted. Underlined glycoforms were analyzed by activated ionelectron capture dissociation (AI-ECD) FT-ICR MS/MS. ECD FT-ICR positive-ion mass spectra for synthetic hinge region peptides: (A) V-P-S-T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S-NH 2 . All allowable cleavages are detected: i.e., all N-Cα bonds except those of prolines are cleaved. (B) V-P-S-T-P-P-T-P-(GalNAc)S-P-S-T-P-P-T-P-S-P-S-NH 2 . The fragmentation pattern allows for unambiguous localization of glycosylation to S9; (C) V-P-S-(GalNAc)T-P-P-T-P-S-P-S-T-P-P-T-P-S-P-S-NH 2 .
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Measured
The fragmentation pattern allows localization of glycosylation to S3/T4; (D) V-P-S-(GalNAc)T-P-P-(GalNAc)T-P-(GalNAc)S-P-(GalNAc)S-T-P-P-(GalNAc)T-P-S-P-S-NH 2 . The fragmentation pattern unambiguously localizes four of the glycosylations (to T7, S9, S11 and T15) and the final glycosylation to S3/T4. Nterminal c fragment ions and C-terminal z(•) fragment ions are indicated above and below each IgA1 HR segment, respectively. ECD FT-ICR positive-ion mass spectrum obtained from a 1:1 mixture of the peptides, 7-HP and 9-HP (V-P-S-T-P-P-(GalNAc)T-P-S-P-S-T-P-P-T-P-S-P-S-NH 2 and V-P-S-T-P-P-T-P-(GalNAc)S-P-S-T-P-P-T-P-S-P-S-NH 2 ). The two species have identical masses; however, the ECD fragmentation pattern reveals different sites of glycosylation. Absence of C 6 +GalNAc and C 1 0 serves to locate the sites of glycan attachment at T7 and S9 within the mixture. 3+ ions from the Oglycosylated IgA1 hinge region peptide. Fifteen (of thirty) peptide backbone bonds are broken (notation is as in Fig. 6 ). The product ions uniquely localize 3 GalNAc-Gal disaccharides to T 225 , T 228 , and S 230 , and a GalNAc to S 232 . 
